BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
More: FinSMEs, Endpoints News, Fierce Biotech, BioSpace, GEN - Genetic Engineering and Biotechnology News, American Chemical Society, WebProNews, BrainChild Bio, Inc.
- FinSMEs: BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
-
Endpoints News / Kyle LaHucik: BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
- Also at: Fierce Biotech, BioSpace, GEN - Genetic Engineering and Biotechnology News, American Chemical Society, WebProNews, BrainChild Bio, Inc.